Neoplasms

All Conditions

Rare Diseases

Glioma

Neoplasms, Neuroepithelial

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Glandular and Epithelial

Neoplasms, Nerve Tissue

Neuroepithelioma

Stefan Sunaert, MD, PhD

Uwe Himmelreich, PhD

In this study, we evaluate the role of diffusion kurtosis imaging (DKI) and MR spectroscopy (MRS), two advanced imaging techniques in magnetic resonance (MR) in grading and detection of microscopic infiltrating tumour in gliomas. These parameters are of utmost importance in optimal choice and planning of treatment.

Patients treated with gliomatous brain tumours are included voluntarily. They undergo one imaging session on a 3T MR scanner prior to treatment.

DKI data are quantitively analyzed in order to estimate specific parameters in normal appearing white matter, grey matter, tumor and peritumoral edema. MRS data are analyzed quantitatively and qualitatively with peak integration, ratio calculation and classification algorithms. Histological confirmation is obtained at subsequent surgery.

Information from this study can be of significant importance in avoiding brain biopsies. Furthermore, information on microscopic tumour spread can be used during neurosurgery or in radiotherapy planning. An important advantage of these advanced MR techniques is the non-invasivity and the lack of ionizing radiation, two important issues in this relatively young patient population.

standard neurosurgical procedure to obtain specimens; standard histopathological examination

Advanced MR Techniques in Detection of Tumor Infiltration and Grading in Gliomas

Diffusion Kurtosis Imaging en MR Spectroscopy in Grading and the Characterization of Tumour Infiltration in Gliomas

Universitaire Ziekenhuizen KU Leuven

Amino Acids

All Drugs and Chemicals

Tyrosine

solene querellou, MD

Role of 18F-FET PET for grading gliomas according to 2016 WHO classification: value of quantitative and qualitative data obtained by 18F-FET PET for differentiating low grade glioma (WHO II) versus high grade gliomas (WHO III and IV)

The management and prognosis of patients with glioma is highly dependent on the tumour grade according to the new 2016 classification of the World Health Organization (WHO), which incorporates molecular characteristics. Standard magnetic resonance imaging (MRI) enhanced by contrast is the basis of imaging primary brain tumours including gliomas. Nevertheless MRI specificity to type glioma is limited. Recently, positron emission tomography (PET) molecular imaging using radiolabeled amino acids or their analogues has been recommended by the Neuro-Oncology Response Assessment (RANO) working group for differential diagnosis of brain lesions, non-invasive classification of glial tumours, prognostic value, tumour delineation, stereotactic biopsy radiotherapy planification and treatments follow-up, to provide additional informations beyond MRI on biological processes such as cell proliferation, membrane biosynthesis, glucose consumption and absorption of amino acid analogues. Among the radiotracers used in PET, radiolabeled amino acids or their analogues are increasingly used in clinical routine for glioma imaging. Although most previous PET studies focused on brain gliomas used L-\[methyl- 11 C\] -methionine (11C-MET), the fluorinated amino acid analogue O - (2-\[ 18 F\] fluoroethyl) -L-tyrosine (18F-FET) appeared to be a favorable marker for clinical routine due to his longer half-life than Carbone 11. Recent european guidelines attempt to provide some guidance on the performance and interpretation of molecular imaging. The authors recommend a static (20-40 mn after injection (Pi)) or dynamic PET acquisition (40-50 mn from injection). A visual analysis can be completed by a quantitative analysis which consists to measure mean and maximal tumour activity uptake values (SUVmean and SUVmax) and their respective tumour to background ratios (TBRmean and TBRmax). Although the mean physiological brain activity uptake is well defined, the measurement of mean glioma activity uptake is less clear. Indeed, TBRmean depends on the delineation of the tumour ROI and/or VOI. Most often previously, VOI was determined by a 3D contouring process using a tumour-to-brain ratio of at least 1.6 at the beginning of the scan, threshold defined on a brain gliomas biopsy-controlled study. Moreover, Albert et al. emphasized the interest of early TBRmax.To our knowledge, none study evaluated others parameters as SUVmax, SUVmean and TBRmean in early period. In this context, the aim of this study was to compare quantitative and qualitative PET parameters between Low Grade Glioma and High Grade Glioma.

18F-Fluoro-Ethyl-Tyrosine (FET) Positron Emission Tomography (PET) and Grading Glioma

Role of 18F-Fluoro-Ethyl-Tyrosine (FET) Positron Emission Tomography (PET) for Grading Glioma

All collected data that underlie results in a publication

study mean value of SUVmax obtained by 18F-FET PET between 2 groups (glioma II vs glioma III-IV)

study mean value of TBRmax obtained by 18F-FET PET between 2 groups (glioma II vs glioma III-IV)

study mean value of SUVmean obtained by 18F-FET PET between 2 groups (glioma II vs glioma III-IV)

study mean value of TBRmean obtained by 18F-FET PET between 2 groups (glioma II vs glioma III-IV)

study mean value of SUVpeak obtained by 18F-FET PET between 2 groups (glioma II vs glioma III-IV)

study mean value of MTV obtained by 18F-FET PET between 2 groups (glioma II vs glioma III-IV)

study mean value of TLG obtained by 18F-FET PET between 2 groups (glioma II vs glioma III-IV)

study mean value of SUVmin obtained by 18F-FET PET between 2 groups (glioma II vs glioma III-IV)

study qualitative data obtained by 18F-FET PET between 2 groups (glioma II vs glioma III-IV)

study inter and intra observers agreement

study diagnostic accuracy of clinical data

study diagnostic accuracy of biological data

study the prognostic value of PET criteria on PFS

study the prognostic value of PET criteria on OS

modification of PET criteria between PET Baseline and PET at follow-up and their prognostic value on PFS

modification of PET criteria between PET Baseline and PET at follow-up and their prognostic value on OS

Study title	NCT ID	Conditions	Eligibility	Organization
Advanced MR Techniques in Detection of Tumor Infiltration and Grading in Gliomas	NCT01225003	Gliomas	18 Years -	Universitaire Ziekenhuizen KU Leuven
18F-Fluoro-Ethyl-Tyrosine (FET) Positron Emission Tomography (PET) and Grading Glioma	NCT04001257	Positron Emissi... Glioma	18 Years -	University Hospital, Brest
Advanced MR Techniques in Detection of Tumor Infiltration and Grading in Gliomas	NCT01225003	Gliomas	18 Years -	Universitaire Ziekenhuizen KU Leuven

Spots Global Cancer Trial Database for grading

Every month we try and update this database with for grading cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for grading

Every month we try and update this database with for grading cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for grading cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.